Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
| Autor: | Choi, Joshua1, Khan, Amir M.1 AKhan@mercy.com, Jarmin, Michael1, Goldenberg, Naila1, Glueck, Charles J.1, Ping Wang1 |
|---|---|
| Zdroj: | Lipids in Health & Disease. 7/24/2017, Vol. 16, p1-11. 11p. 7 Charts, 2 Graphs. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|